Anthem Biosciences Limited (ANTHEM)
Investor Presentation
AI summary
- Q1FY27 consolidated revenue 4,182 Mn, down 22.6% y-y; EBITDA 1,755 Mn, margin 39.6% (+153 bps y-y); PAT 1,199 Mn, margin 27.1%
- CRDMO segment revenue 3,408 Mn (-24.7% y-y); Specialty Ingredients 774 Mn (-11.5% y-y)
- Net cash position strong at 17,197 Mn as of June 30, 2026
- Chairman: demand remains strong; delivery timing shifted to H2FY27
- Margin improvement driven by cost efficiencies, yield optimization, and productivity
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ANTHEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ANTHEM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Anthem Biosciences Limited
Important.
The summary above is generated automatically from Anthem Biosciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.